Search Results

Phasix™ ST Umbilical Hernia Patch is indicated for use in the reinforcement of soft tissue, where weakness exists, in procedures involving the repair of umbilical hernias.

Phasix™ ST Umbilical Hernia Patch is a sterile, single-use device for prescription use only. It is a self-expanding, fully resorbable mesh with a resorbable hydrogel coating and a positioning pocket and strap. Phasix™ ST Umbilical Hernia Patch is comprised of 2 layers of poly-4hydroxybutyrate (P4HB), with the posterior side being co-knitted with polyglycolic acid (PGA) fibers, identical to the mesh component of the secondary predicate device (Phasix™ ST Mesh with Open Positioning System). P4HB degrades through hydrolysis and a hydrolytic enzymatic digestive process and is essentially completely resorbed in 12-18 months. Phasix™ ST Umbilical Mesh is coated on the PGA surface with a resorbable, chemically modified sodium hyaluronate (HA), carboxymethylcellulose (CMC), and polyethylene glycol (PEG) based hydrogel. The hydrogel is identical to both the primary predicate device (Ventralex™ ST Hernia Patch (K101928) and the secondary predicate device (Phasix™ ST Mesh with Open Positioning System, K190185). The fascial side of the mesh allows for a prompt fibroblastic response through the interstices of the mesh, allowing for complete tissue ingrowth. The visceral side of the mesh is the resorbable hydrogel coating, which separates the mesh from underlying tissues and organ surfaces to help minimize tissue attachment to the mesh. Shortly after hydration in saline, the coating becomes a hydrated gel that is resorbed from the site in less than 30 days. Phasix™ ST Umbilical Hernia Patch contains SorbaFlex™ Memory Technology, which provides memory and stability to the mesh, facilitating ease of initial insertion, proper placement and fixation of the device. The SorbaFlex™ Memory Technology is comprised of an extruded polydioxanone (PDO) resorbable monofilament contained within a knitted P4HB containment sleeve. PDO is resorbed within 24-32 weeks. The PDO ring and hybrid positioning straps (comprised of P4HB and polypropylene materials that are connected by overlapping the materials and sewing them together with clear PP monofilament, with a delineation marker dyed blue with [phthalocyaninato(2-)] copper), are based on the design of the primary predicate Ventralex™ ST Hernia Patch (K101928). The subject device has the identical intended use as the primary and predicate devices; soft tissue repair/reinforcement.

The provided document does not describe acceptance criteria for a software device or a study proving that a software device meets those criteria.

Instead, the document is a 510(k) premarket notification summary for a physical medical device: Phasix™ ST Umbilical Hernia Patch.

Therefore, I cannot provide the requested information regarding acceptance criteria and studies for a software device.

The document discusses the following types of testing for the physical medical device:

• Biocompatibility Testing: Conducted in accordance with ISO 10993-1. Many tests were not repeated as the materials were the same as previously cleared predicate devices. Tests included material chemical characterization (gravimetric analysis, GCMS, LCMS-UV-CAD, HS-GCMS, ICPMS, GPC), cytotoxicity, sensitization, irritation/intracutaneous reactivity, acute systemic toxicity, material mediated pyrogenicity, LAL, subacute/subchronic/chronic toxicity, genotoxicity (AMES, Mouse Lymphoma), and implantation tests.
• Product Testing (Performance Testing): This included "Substantial Equivalency Testing" covering physical characteristics (mesh weave, pore size, thickness, weight per unit area, stiffness, dimensions) and functional characteristics (ball burst strength, suture retention strength, tear strength, PGA pull-out strength, three-tack pluck force, gel disruption analysis). It also included functional testing of the subject device (25-degree recoil, containment sleeve puncture, strap attachment strength, pocket integrity), resorption profile of the ring and containment sleeve (in-vitro degradation of PDO), design validation usability testing, and human factors/simulated testing.
• Animal Studies: No new animal studies were conducted for the subject device. Instead, the safety and performance were evaluated based on animal and histological data from reference devices (Phasix™ Mesh, Phasix™ ST Mesh) and predicate devices (Phasix™ ST Mesh with Open Positioning System, Ventralex™ ST Hernia Patch). The PDO ring material was previously evaluated in a rat model.

If you have a document pertaining to a software device, please provide that, and I will do my best to extract the requested information.

Ask a specific question about this device

Ask a specific question about this device

The AccuCath Ace™ Intravascular Catheter is inserted into a patient's vascular system to sample blood, monitor blood pressure, or administer fluids intravenously. This device may be used for adult and pediatric patients, including those patients with difficult intravascular access who may have small, fragile, and/or non-palpable vessels, with consideration given to adequacy of vascular anatomy, appropriateness of the solution being infused, and duration of therapy. The AccuCath Ace™ IV Catheter is suitable for use with power injectors.

The AccuCath Ace™ Intravascular Catheter system consists of a radiopaque catheter with a valve mechanism delivered over a guidewire with an atraumatic tip design; a flashback chamber to enhance flashback visualization, and a safety container that prevents sharp injuries. The AccuCath Ace IV Catheter is designed to reduce blood exposure during insertion, for use with ultrasound, and for use with the Cue Needle Tracking System.

The information provided indicates that the AccuCath Ace™ Intravascular Catheter did not undergo a new study to prove it meets acceptance criteria for its current submission. Instead, the submission focuses on demonstrating substantial equivalence to a predicate device (AccuCath™ Intravascular Catheter, K162894) based on a modification to its Indications for Use, which now explicitly includes patients with difficult intravascular access (DIVA).

The document states that a risk analysis determined that no verification or validation activities were required because the modifications to the Indications for Use and labeling "do not include any changes to the design, materials, performance, or risk profile of the cited predicate device."

Therefore, the "acceptance criteria" and "device performance" described below are in reference to the previous clearance of the predicate device and the modifications that had been made to it, for which "Verification, sterilization, biocompatibility, and packaging testing was carried out as necessary for each of these changes at the time of the change." The current submission does not detail these specific tests, their criteria, or results, but rather asserts that the changes "were found to be as safe and as effective and introduced no new or modified risks."

The table below summarizes the information provided regarding the comparison between the subject device (AccuCath Ace™ Intravascular Catheter) and its predicate device (AccuCath™ Intravascular Catheter, K162894), highlighting what is considered "met" based on the substantial equivalence argument rather than new primary testing.

1. Table of Acceptance Criteria and Reported Device Performance

Ask a specific question about this device

Bard® 3DMax™ Mesh is indicated for use in the reinforcement of soft tissue where weakness exists, in the repair of inguinal hernias.

The Bard® 3DMax™ Mesh is anatomically designed to fit the inquinal anatomy. The device is curve shaped and preformed with sealed edges that allow for easier positioning of the device than a traditional flat sheet of mesh in a laparoscopic inguinal hernia repair. The device is constructed of knitted polypropylene monofilaments 7.5 millimeters in diameter. The knit construction allows the mesh to be stretched in both directions in order to accommodate and reinforce tissue defects. The device contains an orientation marker in an M shape with an arrow to facilitate mesh positioning and placement.

This submission, K233402, describes a Special 510(k) for the Bard 3DMax Mesh, which focuses solely on labeling changes to align with European medical device regulations and other devices in the Davol Inc. portfolio. The submission explicitly states:

"No non-clinical or clinical testing was provided in support of this Special 510(k)." and "The purpose of this Special 510(k) is to notify FDA of the changes to the Bard® 3DMax™ Mesh labeling. There are no changes to the device itself."

Therefore, based on the provided document, there are no acceptance criteria or studies associated with this specific submission to describe regarding device performance, as the device itself (materials, design, manufacturing, etc.) has not changed from its predicate, K081010.

To provide the requested information, one would need access to the original 510(k) submission (K081010) that established the substantial equivalence of the device itself, rather than just its labeling.

Since the prompt asks for information from the provided input, and the input explicitly states no testing was done, I cannot fulfill the request for acceptance criteria and study details.

Ask a specific question about this device

The SiteRite™ 9 Ultrasound System is intended for diagnostic ultrasound imaging of the human body performed by appropriately trained healthcare professionals in a medical setting. Specific clinical applications include:

• · Pediatric
• · Peripheral Vessel and Vascular Access
• · Small Organ (breast, thyroid, parathyroid, testicles)
• · Musculo-skeletal (conventional and superficial)
• · Cardiac (adult and pediatric)

The SiteRite™ 9 Ultrasound System is indicated for Vascular, Vascular Access, Interventional, and Superficial Imaging Applications. Typical examinations performed using the SiteRite™ 9 Ultrasound System include:
Vascular: Assessment of vessels in the extremities and neck leading to or coming from the heart, superficial veins in the arms and legs, and vessel mapping. Assessment of superficial thoracic vessels.
Vascular Access: Guidance for PICC, CVC, dialysis catheter, port, PIV, midline, arterial line placement, access to fistula and grafts, and general vein and artery access.
Interventional: Guidance for biopsy and drainage.
Superficial: Assessment of breast, thyroid, parathyroid, testicle, lymph nodes, musculoskeletal procedures, soft tissue structures, and surrounding anatomical structures.

The subject device, the SiteRite™ 9 Ultrasound System ("SiteRite 9 System") is a portable device that features real-time 2D ultrasound imaging for vascular access device placement, which includes vessel measurement tools, vascular access device selection, procedure documentation and electronic connectivity.

The subject SiteRite 9 System is intended to aid in the placement of peripheral and central line vascular access devices and ultimately increase first stick success. The system is the replacement platform for the Site~Rite® 8 Ultrasound System with Cue™ Needle Tracking System and Pinpoint™ GT Needle Technology (i.e., the predicate device) and includes more up-to-date and reliable components aimed at providing improved image quality, while maintaining ease of operation.

The subject SiteRite 9 System can be viewed as the next generation SiteRite™ ultrasound system and is equivalent from a functionality standpoint to its predicate device, to the SiteRite® 8 Ultrasound System with Cue™ Needle Tracking System and Pinpoint™ GT Needle Technology (K182281). The SiteRite 9 System is essentially replacing its predicate device, the SiteRite® 8 Ultrasound System with Cue™ Needle Tracking System and Pinpoint™ GT Needle Technology ("Site~Rite 8 System"), due to the end-oflife obsolescence of its components.

The subject SiteRite 9 System differs from its predicate device, the Site~Rite 8 System (K182281). in that it includes newer, more "state of the art" hardware components resulting in a more efficient and reliable use of the device. Aside from these technical upgrades, most of the previously cleared features of the predicate device are being brought forward.

The subject SiteRite 9 System includes the following main components:

• Ultrasound System Console
• Ultrasound Beamformer
• System Software
• 9 Ultrasound Probe

Additionally, the subject SiteRite 9 System is compatible with the following accessories:

• SiteRite™ Probe Cover Kits
• Site~Rite® Needle Guide Kits
• Pinpoint TM GT Needle Guide Kits
• MER Roll Stand with Mounting Accessory (optional accessory)
• Kickstand with Mounting Accessory (optional accessory)
• Sony Printer UP-X898MD (off-the-shelf, optional accessory)
• USB Storage Device (off-the-shelf, optional accessory)

Here's an analysis of the provided text regarding the acceptance criteria and supporting study for the SiteRite™ 9 Ultrasound System:

1. Table of Acceptance Criteria and Reported Device Performance

The provided FDA 510(k) summary does not include a specific table of quantitative acceptance criteria and corresponding device performance metrics for the SiteRite™ 9 Ultrasound System itself. Instead, it relies on a qualitative comparison to a predicate device and a statement that the device "successfully passed all respective testing" based on applicable standards and guidance documents.

However, based on the text, the overarching acceptance criterion is substantial equivalence to the predicate device (Site~Rite® 8 Ultrasound System with Cue™ Needle Tracking System and Pinpoint™ GT Needle Technology, K182281), particularly in terms of:

• Intended Use: Diagnostic ultrasound imaging of the human body.
• Indications for Use: Pediatric, Peripheral Vessel and Vascular Access, Small Organ, Musculo-skeletal, Cardiac imaging applications, and guidance for procedures.
• Technological Characteristics: Same fundamental scientific technology (piezoelectric material, 2D ultrasound imaging), patient-contacting materials, and software features.
• Safety and Performance: Demonstrated through non-clinical testing to meet relevant safety and performance requirements.

Reported Device Performance:
The document primarily states that the device "passed all respective testing" and that its performance "support[s] substantial equivalence to the predicate device." It also highlights that the SiteRite™ 9 includes "newer, more 'state of the art' hardware components resulting in a more efficient and reliable use of the device" and aims for "improved image quality" compared to its predicate.

2. Sample size used for the test set and the data provenance

The document does not explicitly state the sample size for any specific individual non-clinical test set. The data provenance is internal to Bard Access Systems, Inc. (C.R. Bard, Inc.) through their conducted "extensive verification and validation testing." As this is a non-clinical submission, the data would be laboratory-based and not related to patient retrospective or prospective data.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts

This information is not provided. Given that the testing is non-clinical (primarily bench testing) and relies on compliance with standards rather than expert review of images, the concept of "ground truth" established by experts in the clinical sense is not applicable here.

4. Adjudication method

This information is not provided and is not relevant for the type of non-clinical testing described.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, if so, what was the effect size of how much human readers improve with AI vs without AI assistance

No, a multi-reader multi-case (MRMC) comparative effectiveness study was not done. The device described is an ultrasound system, not an AI-powered diagnostic tool, and the submission explicitly states: "No clinical testing was conducted in support of the SiteRite™ 9 Ultrasound System, as the intended use, indications and technology are equivalent to those of the predicate device."

6. If a standalone (i.e. algorithm only without human-in-the loop performance) was done

No, a standalone performance study in the context of an algorithm's performance was not done. This device is a hardware-software integrated ultrasound system, not an independent algorithm.

7. The type of ground truth used

For the non-clinical tests, the "ground truth" would be defined by engineering specifications, established physical properties, and compliance with recognized standards (e.g., acoustic output limits, electrical safety parameters, image quality metrics as defined by test phantoms or calibrated equipment). For example, "Acoustic Safety Testing" would have acceptance criteria based on standard limits for acoustic output, and the "ground truth" is that the device's output should not exceed those limits when measured.

8. The sample size for the training set

This information is not applicable and not provided. The SiteRite™ 9 Ultrasound System is not described as an AI/ML device that requires a training set for model development. It's a traditional medical imaging device.

9. How the ground truth for the training set was established

This information is not applicable and not provided, as there is no training set mentioned for an AI/ML model.

Ask a specific question about this device

The Aspirex™ Thrombectomy System is indicated for the removal of acute emboli and thrombi from vessels of the peripheral venous system.

The 6F and 8F Aspirex™ Thrombectomy Systems are indicated for the removal of acute emboli and thrombi from hemodialysis access grafts and native arteriovenous fistulas.

The Aspirex™ Thrombectomy System-composed of the Aspirex™ Thrombectomy Catheter Set and the Drive System-is designed for efficient thrombus removal with strong, continuous, and controlled aspiration. The Drive System is composed of the control unit, a motor, and a footswitch. The Drive System is small and portable, and designed for simple, quick set up and ease of use.

The Aspirex™ Thrombectomy Catheter Set is composed of multiple components, including the Aspirex™ Thrombectomy Catheter, the Aspirex™ Guidewire, collecting bag, and sterile drape. The Aspirex™ Thrombectomy Catheter consists of a braided shaft, to add strength and torque, through which runs a helix. The catheter shaft connects to a metallic head constructed with a side window(s) at the distal end. The head has a smooth, rounded, atraumatic shape so unintentional contact with the vessel wall will not cause damage to the vessel. Contact with the vessel wall is not necessary for the catheter to exert its effect. An ergonomic handle, connected to the catheter shaft at the proximal end, connects to the motorized Drive System via a magnetic clutch. The entire catheter tracks over the Aspirex™ Guidewire previously navigated across the thrombus/embolus.

The provided text is a 510(k) summary for the Aspirex™ Thrombectomy System. This document focuses on demonstrating substantial equivalence to a predicate device, not on proving a device meets specific acceptance criteria through a study with predefined performance metrics like those typically found in an AI/ML context.

Therefore, many of the requested items (e.g., acceptance criteria table, sample sizes, expert ground truth establishment, MRMC studies, standalone performance, training set details) are not applicable or not provided in this type of FDA submission for a medical device that processes human biological material.

However, I can extract information related to the device, its intended use, and the performance data that was reviewed (rather than generated by a specific study to meet acceptance criteria).

Here's what can be extracted and what cannot:

1. A table of acceptance criteria and the reported device performance:

• Not Applicable/Not Provided: This document does not present a table of specific acceptance criteria (e.g., target specificity, sensitivity, or image quality metrics) or reported device performance against those criteria in the way an AI/ML device would. Instead, it discusses the device's functional specifications and clinical outcomes in terms of existing literature and clinical study reports.

Here's information related to the device specifications that might be considered "performance" in a mechanical sense, but not quantitative "acceptance criteria" for an AI/ML model:

2. Sample sizes used for the test set and the data provenance:

• Not Provided: The document states that a "review of clinical data from scientific literature and clinical study reports" was performed. It does not specify a "test set" sample size, as it's a review of existing data, not a new, controlled study to validate a new claim against a test set.
• Data Provenance: The data provenance is "scientific literature and clinical study reports." The country of origin and whether it was retrospective or prospective is not specified.

3. Number of experts used to establish the ground truth for the test set and the qualifications of those experts:

• Not Applicable/Not Provided: This is not a study involving expert readers establishing ground truth for a diagnostic AI/ML device. The "performance data" is derived from a review of clinical outcomes reported in existing literature and studies, which reflects real-world clinical results, not expert "ground truth" for a device's diagnostic performance.

4. Adjudication method (e.g. 2+1, 3+1, none) for the test set:

• Not Applicable/Not Provided: No adjudication method is mentioned as this is not a study comparing human performance or diagnostic accuracy.

5. If a multi-reader multi-case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance:

• Not Applicable/Not Provided: This is a physical medical device (thrombectomy system), not an AI/ML diagnostic aid. Therefore, an MRMC study and effects on human reader performance are irrelevant.

6. If a standalone (i.e. algorithm only without human-in-the-loop performance) was done:

• Not Applicable/None: This is a physical medical device (thrombectomy system) that is used by humans, not an algorithm.

7. The type of ground truth used:

• Clinical Outcomes/Patency Rates: The "performance data" relied on reviewing "primary patency rates" in hemodialysis access grafts and native arteriovenous fistulas. This is long-term clinical outcome data, not a diagnostic "ground truth" established by experts or pathology for a specific event.

8. The sample size for the training set:

• Not Applicable/Not Provided: This is not an AI/ML device, so there is no "training set." The device's design and manufacturing are identical to the predicate.

9. How the ground truth for the training set was established:

• Not Applicable/Not Provided: No training set exists for this type of device.

Summary of Device Performance (from the document):

The performance data reviewed for the Aspirex™ Thrombectomy System focused on:

• Type of data: Clinical data from scientific literature and clinical study reports.
• Focus: Device performance and clinical outcomes of percutaneous mechanical thrombectomy with the Aspirex™ Thrombectomy System for the removal of occlusions from hemodialysis access grafts and native arteriovenous fistulas.
• Key Metric Analyzed: Primary patency rates.
• Conclusion: Vascular access patency rates after treatment with the Aspirex™ device are similar to those observed with treatment with other mechanical thrombectomy devices or surgery. Sub-group analyses confirmed these results. The review concluded that the use of the Aspirex™ Thrombectomy System in these expanded indications "does not raise new questions of safety and effectiveness" and "provides satisfactory clinical outcomes in terms of patency rates and the functioning of hemodialysis vascular access."

Ask a specific question about this device

The Highlander™ 014 PTA Balloon Dilatation Catheted for use in percutaneous transluminal angioplasty (PTA) of the peripheral vasculature, including femoral, popliteal and renal arteries. This device is also indicated for post-dilatation of balloon expanding stents in the peripheral vasculature. This catheter is not for use in coronary arteries.

The Highlander™ 014 PTA Balloon Dilatation Catheter is a small vessel balloon catheter consisting of an over the wire catheter with a balloon fixed at the distal tip. The proprietary non-compliant, low-profile balloon is designed to provide consistent balloon diameters and lengths even at high pressures. For all balloon lengths, radiopaque markers delineate the working length of the balloon and aid in balloon placement. For balloon lengths of 100mm and greater, two radiopague markers are positioned on the distal portion of the balloon and one radiopaque marker is positioned on the proximal portion of the balloon to differentiate between the distal and proximal ends of the balloon. The catheters include an atraumatic tip to facilitate advancement of the catheter to and through the stenosis. A silicone-based, hydrophobic coating is present on the distal segment of the shaft and balloon. Highlander™ 014 is compatible with 0.014" guidewires. The proximal portion of the catheters include a female luer lock hub connected to the inflation lumen, and a female luer lock hub connected to the guidewire lumen.

Packaged with every product is a profile reducing sheath that is positioned over the balloon for protection before use. A stylet is placed into the tip of the catheter to aid in rewrap/refolding of the balloon. These products are not made with natural rubber latex.

The GeoAlign™ Marking System is a non-radiopaque ruler on the catheter shaft measured from the distal tip. The GeoAlign™ markings are designated on the catheter shaft by 1cm increment bands with an accuracy within ±1mm. The distance from the distal catheter tip is labeled in 10cm increments. Thicker bands denote the midway point (5cm) between the labeled distances. The GeoAlign™ Marking System is designed to be used as a tool to externally measure the intravascular advancement and/or retraction of the catheter. This can provide an intravascular reference regarding the location of the distal tip of the catheter or an approximate intravascular length measurement between two points. The GeoAlign™ Marking System may also facilitate geographic alignment of an adjunctive therapy that includes the same GeoAlign™ Marking System.

The provided text is a 510(k) summary for the Highlander™ 014 PTA Balloon Dilatation Catheter. This document details the device's characteristics, indications for use, and a comparison to a predicate device to demonstrate substantial equivalence. It is important to note that this document does not contain information about studies related to AI/ML device performance, ground truth establishment, or expert reviews as it is for a physical medical device (balloon catheter).

Therefore, this response will focus on the acceptance criteria and performance data for the physical device as described in the provided text.

1. Table of Acceptance Criteria and Reported Device Performance

The document lists various in vitro tests performed to demonstrate substantial equivalence. It does not provide specific numerical acceptance criteria or detailed quantitative performance results for each test. Instead, it states a general conclusion for each category: "The results from these tests demonstrate that the technological characteristics and performance criteria of the Highlander™ 014 PTA Balloon Dilatation Catheter are substantially equivalent to the predicate device, and that it can perform in a manner equivalent to devices currently on the market for the same intended use." and "met all predetermined acceptance criteria of design verification and validation as specified by applicable standards, guidance, test protocols and/or customer inputs."

However, based on the categories of tests listed, a general representation of acceptance criteria and reported performance is as follows:

2. Sample Size for the Test Set and Data Provenance

The document does not specify the sample sizes used for each in vitro test. The tests are "in vitro" (performed in a lab setting, not on human or animal subjects). Therefore, there is no data provenance in terms of country of origin or retrospective/prospective nature as would be relevant for clinical studies.

3. Number of Experts and Qualifications

This information is not applicable. The evaluations described are in vitro engineering and materials tests, not clinical studies requiring expert interpretation of diagnostic images or patient outcomes.

4. Adjudication Method

This information is not applicable as there is no mention of a ground truth needing adjudication by human experts in the context of this device's testing.

5. Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study

No. This type of study is typically performed for AI-driven diagnostic imaging devices to assess the impact of AI assistance on human reader performance. The Highlander™ 014 PTA Balloon Dilatation Catheter is a physical medical device, not an AI/ML diagnostic tool.

6. Standalone Performance Study

Yes, the in vitro tests conducted on the Highlander™ 014 PTA Balloon Dilatation Catheter can be considered a standalone performance study. These tests evaluated the device's physical and mechanical properties and biocompatibility independent of human use in a clinical setting. The conclusion states that "The subject device, the Highlander™ 014 PTA Balloon Dilatation Catheter, met all predetermined acceptance criteria of design verification and validation as specified by applicable standards, guidance, test protocols and/or customer inputs." This indicates a standalone assessment of its performance against established benchmarks.

7. Type of Ground Truth Used

The "ground truth" for the in vitro tests would be defined by the technical specifications, industry standards, relevant FDA guidance documents, and internal risk assessment procedures. For example, for physical dimensions, the ground truth is the specified design dimension; for burst pressure, it's the minimum acceptable pressure according to device-specific or industry standards. For biocompatibility tests, the ground truth is the pass/fail criteria established by recognized international standards (e.g., ISO 10993 series).

8. Sample Size for the Training Set

This information is not applicable. The described tests are for a physical medical device and do not involve AI/ML algorithms that require training data.

9. How the Ground Truth for the Training Set was Established

This information is not applicable for the reasons stated in point 8.

Ask a specific question about this device

The WavelinQ™ Generator is used to deliver RF energy via an assortment of surgical devices to cut and coagulate different kinds of tissue.

The WavelinQ™ Generator is a high frequency isolated generator that utilizes electrical current to deliver radiofrequency (RF) energy to the catheter electrode for formation of a vascular fistula. The generator offers a receptacle for a monopolar handpiece. The WavelinQ™ Generator is intended to be used with the currently marketed and cleared device WavelinQ™ EndoAVF System (K192239). The generator has one setting (AV1) equivalent to the mode (Cut T, 60W, 0.7s) of the predicate device, ESU-1 Electrosurgical Generator, that is used during the WavelinQ™ EndoAVF System procedure. This mode is set to deliver energy at 60 Watts for 0.7 seconds. The generator has a return electrode contact, for use with a split ground pad, and quality monitoring system (NEM) to reduce the risk of patient burns at the return electrode site. The pad-sensing feature allows the user to use only a split return electrode, also referred to as a split ground pad.

The device consists of a generator and power cord and is packaged with a User's Guide in a cardboard shipping box with protective foam inserts. The main device components are a front panel containing the power button, LED numeric display, alarm and return electrode indicator lights, and connector ports for accessories, a back panel consisting of volume controls, a power cord outlet and fuse, and internal components (printed circuit boards, speakers, cabling).

The provided text is a 510(k) Summary for a medical device (WavelinQ™ Generator) and does not contain information about an AI/ML-based device. Therefore, it is not possible to describe acceptance criteria, a study proving device performance, or details regarding AI/ML ground truth, expert opinions, or MRMC studies, as none of that information is applicable to this document.

The document discusses the substantial equivalence of the WavelinQ™ Generator to a predicate device based on its intended use, indications for use, technological characteristics, and performance testing for electrical safety, mechanical aspects, reliability, and functionality. The tests performed are standard for electro-surgical devices and do not involve AI/ML components or human interpretation of outputs that would require multi-reader studies or complex ground truth establishment for AI model evaluation.

Ask a specific question about this device

The Aspirex™ Thrombectomy System is indicated for the removal of acute emboli and thrombi from vessels of the peripheral venous system.

The Aspirex™ Thrombectomy System-composed of the Aspirex™ Thrombectomy Catheter Set and the Drive System-is designed for efficient thrombus removal with strong, continuous, and controlled aspiration The Drive System is composed of the control unit, a motor, and a footswitch. The Drive System is small and portable, and designed for simple, quick set up and ease of use.

The Aspirex™ Thrombectomy Catheter Set is composed of multiple components, including the Aspirex™ Thrombectomy Catheter, the Aspirex™ Guidewire, collecting bag, and sterile drape. The Aspirex™ Thrombectomy Catheter consists of a braided shaft, to add strength and torque, through which runs a helix. The catheter shaft connects to a metallic head constructed with a side window(s) at the distal end. The head has a smooth, rounded, atraumatic shape so unintentional contact with the vessel wall will not cause to the vessel. Contact with the vessel wall is not necessary for the catheter to exert its effect. An ergonomic handle, connected to the catheter shaft at the proximal end, connects to the motorized Drive System via a magnetic clutch. The entire catheter tracks over the Aspirex™ Guidewire previously navigated across the thrombus/embolus.

The Aspirex™ Guidewire has a LubriSkin PTFE-coated nitinol core wire with a gold-plated tungsten tip coated with DSM ComfortCoat® hydrophilic coating. The guidewire is used to initially cross through the area to be treated.

The provided text describes a medical device, the Aspirex™ Thrombectomy System, and its performance data to demonstrate substantial equivalence to a predicate device. However, it does not contain information about acceptance criteria or a study related to an AI/algorithm-based device's performance, human reader assistance, or ground truth establishment for such a device.

The study described is a GLP animal study comparing the Aspirex™ catheter (test article) to the Indigo Aspiration Catheter (control article) in healthy veins. This study assesses the physical and biological performance of the catheters, not an AI algorithm.

Therefore, I cannot provide the requested information regarding AI device acceptance criteria and performance based on the input text. The text does not discuss:

1. A table of acceptance criteria and the reported device performance for an AI/algorithm.
2. Sample size for a test set (related to AI data) or data provenance.
3. Number of experts or their qualifications for establishing ground truth for AI data.
4. Adjudication method for an AI test set.
5. Multi-reader multi-case (MRMC) comparative effectiveness study for AI assistance.
6. Standalone performance of an AI algorithm.
7. Type of ground truth used for AI (e.g., expert consensus, pathology, outcomes data).
8. Sample size for a training set for an AI algorithm.
9. How ground truth for a training set for an AI algorithm was established.

The document focuses on the mechanical and biological performance of a physical medical device (thrombectomy system) through in vitro and animal studies, and its substantial equivalence to a predicate device, as required for FDA 510(k) clearance.

Ask a specific question about this device

The Conquest™ 40 PTA Dilatation Catheter is recommended for use in Percutaneous Transluminal Angioplasty of the femoral, iliac, and renal arteries and for the treatment of native or synthetic arteriovenous dialysis fistulae. This device is also recommended for post-dilatation of stents in the peripheral vasculature. This catheter is not for use in coronary arteries.

The Atlas™ Gold PTA Dilation Catheter is indicated for use in Percutaneous Transluminal Angioplasty of the peripheral vasculature, including the illac and femoral veins, and for the treatment of obstructive lesions of native or synthetic arteriovenous dialysis fistulae. This device is also indicated for post-dilatation of stents and stent grafts in the peripheral vasculature. This catheter is not for use in coronary arteries.

The Vida™ PTV Dilatation Cather is recommended for Percutaneous Transluminal Valvuloplasty (PTV) of the pulmonary valve in the following:
· A patient with isolated pulmonary valve stenosis.
· A patient with valvular pulmonary stenosis with other minor congenital heart disease that does not require surgical intervention.

The Vida™ BAV Balloon Valvuloplasty Catheter is indicated for balloon aortic valvuloplasty.

The Conquest™ 40 PTA Dilatation Catheter is a high-performance balloon catheter consisting of an over-the-wire catheter with a balloon fixed at the distal tip. The proprietary ultra non-compliant, low profile balloon is designed to provide consistent balloon diameters and lengths even at high pressures. Two radiopaque markers delineate the working length of the balloon and aid in balloon placement. The coaxial catheter includes a tapered atraumatic tip to facilitate advancement of the catheter to and through the stenosis. The proximal portion of the catheter includes a female luer lock hub connected to the inflation lumen, and a female luer-lock hub connected to the quidewire lumen. The over-the-wire catheter is compatible with 0.035" guidewires and is available in 50cm and 75cm working lengths. Packaged with every product is a profile reducing sheath that is positioned over the balloon for protection before use. A re-wrapping tool is also provided on the catheter shaft. A stylet is placed into the tip of the catheter to aid in re-wrap/refolding of the balloon. This product is not manufactured with any latex.

The Atlas™ Gold PTA Dilatation Catheter is a high-performance balloon catheter consisting of an over-the-wire catheter with a balloon fixed at the distal tip. The proprietary non-compliant, low profile balloon is designed to provide consistent balloon diameters and lengths even at high pressures. Two radiopaque markers delineate the working length of the balloon and aid in balloon placement. The coaxial catheter includes a tapered atraumatic tip to facilitate advancement of the catheter to and through the stenosis. The proximal portion of the catheter includes a female luer lock hub connected to the inflation lumen, and a female luer-lock hub connected to the guidewire lumen. The over-the-wire catheter is compatible with .035" guidewire and is available in 80 cm and 120 cm working lengths.
Packaged with every product is a profile reducing sheath that is positioned over the balloon for protection before use. A re-wrapping tool is also provided on the catheter shaft to aid in re-wrap/refolding of the balloon. This product is not manufactured with any natural rubber latex.

The Vida™ PTV Dilatation Catheter is a high-performance balloon catheter consisting of an over-the-wire catheter with a balloon fixed at the distal tip. The proprietary, noncompliant, low profile balloon is designed to provide consistent balloon diameters and lengths even at high pressures. Two radiopaque markers delineate the working length of the balloon and aid in balloon placement. The coaxial catheter includes an atraumatic tip to facilitate advancement of the catheter to and through the valve. The over-the-wire catheter is compatible with .035" guidewire and is available in 100 cm working length. The proximal portion of the catheter includes a female luer-lock hub connected to the inflation lumen, and a female luer-lock hub connected to the guidewire lumen.
Packaged with every product is a profile reducing sheath that is positioned over the balloon for protection before use. A re-wrapping tool is also provided on the catheter shaft. This product is not manufactured with any latex.

The Vida™ BAV Balloon Valvuloplasty Catheter is a high-performance balloon catheter consisting of an over-the-wire catheter with a balloon fixed at the distal tip. The proprietary, non-compliant, low profile balloon is designed to provide consistent balloon diameters and lengths. Two radiopaque markers delineate the working length of the balloon and aid in balloon placement. The coaxial catheter includes an atraumatic tip to facilitate advancement of the catheter to and through the valve. The over-the-wire catheter is compatible with .035" guidewire and is available in 100 cm working length. The proximal portion of the catheter includes a female luer-lock hub connected to the inflation lumen, and a female luer-lock hub connected to the guidewire lumen.
Packaged with every product is a profile reducing sheath that is positioned over the balloon for protection before use. A re-wrapping tool is also provided on the catheter shaft. This product is not manufactured with any latex.

The provided document describes the substantial equivalence determination for several medical devices, specifically balloon dilatation and valvuloplasty catheters. It does not present acceptance criteria or performance data for an AI/ML-driven medical device. Instead, it focuses on the engineering and material characteristics of physical medical devices and their comparison to previously cleared predicate devices.

Therefore, I cannot provide a response based on the requirements of your prompt, as the document does not contain information related to:

1. AI/ML performance testing: The document details physical device performance tests (e.g., trackability, burst strength, fatigue, biocompatibility), not AI model performance metrics like sensitivity, specificity, or AUC.
2. Test/training sets for AI/ML: There is no mention of data sets, sample sizes for AI training or testing, data provenance, or ground truth establishment relevant to an AI algorithm.
3. Expert adjudication or MRMC studies: These are concepts specific to the evaluation of AI systems, typically involving human readers or experts, which are not applicable to the physical devices described in this submission.

The document states: "The subject devices...met all predetermined acceptance criteria of design verification and validation as specified by applicable standards, guidance, test protocols and/or customer inputs." However, it does not specify what those "predetermined acceptance criteria" are for each test, nor does it present the reported device performance in detail (e.g., actual burst pressures achieved vs. minimum required). It lists the types of tests performed.

To fulfill your request, the input document would need to describe the development and validation of an AI/ML component, including its specific acceptance criteria and the results of studies demonstrating its performance.

Ask a specific question about this device